JP7592320B2 - ソルチリン受容体を標的化し血管擬態を阻害するための方法及び化合物 - Google Patents

ソルチリン受容体を標的化し血管擬態を阻害するための方法及び化合物 Download PDF

Info

Publication number
JP7592320B2
JP7592320B2 JP2021534405A JP2021534405A JP7592320B2 JP 7592320 B2 JP7592320 B2 JP 7592320B2 JP 2021534405 A JP2021534405 A JP 2021534405A JP 2021534405 A JP2021534405 A JP 2021534405A JP 7592320 B2 JP7592320 B2 JP 7592320B2
Authority
JP
Japan
Prior art keywords
cancer
compound
seq
sortilin
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021534405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535209A (ja
JP2021535209A5 (cg-RX-API-DMAC7.html
Inventor
リシャール ベリヴォー
ボラーヌ アナビー
ミシェル デムール
アラン ラロック
ジャン クリストフ キュリー
アラン ズゲーブ
Original Assignee
トランスフェール プリュ エス.ウ.セ.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トランスフェール プリュ エス.ウ.セ. filed Critical トランスフェール プリュ エス.ウ.セ.
Publication of JP2021535209A publication Critical patent/JP2021535209A/ja
Publication of JP2021535209A5 publication Critical patent/JP2021535209A5/ja
Application granted granted Critical
Publication of JP7592320B2 publication Critical patent/JP7592320B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/083—Neurotensin
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021534405A 2018-08-24 2019-08-26 ソルチリン受容体を標的化し血管擬態を阻害するための方法及び化合物 Active JP7592320B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862722726P 2018-08-24 2018-08-24
US62/722,726 2018-08-24
US201962804063P 2019-02-11 2019-02-11
US62/804,063 2019-02-11
PCT/CA2019/051170 WO2020037434A1 (en) 2018-08-24 2019-08-26 Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry

Publications (3)

Publication Number Publication Date
JP2021535209A JP2021535209A (ja) 2021-12-16
JP2021535209A5 JP2021535209A5 (cg-RX-API-DMAC7.html) 2022-08-29
JP7592320B2 true JP7592320B2 (ja) 2024-12-02

Family

ID=69591094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534405A Active JP7592320B2 (ja) 2018-08-24 2019-08-26 ソルチリン受容体を標的化し血管擬態を阻害するための方法及び化合物

Country Status (8)

Country Link
US (1) US20220000971A1 (cg-RX-API-DMAC7.html)
EP (1) EP3844190A4 (cg-RX-API-DMAC7.html)
JP (1) JP7592320B2 (cg-RX-API-DMAC7.html)
CN (1) CN113286820B (cg-RX-API-DMAC7.html)
AU (1) AU2019324747A1 (cg-RX-API-DMAC7.html)
CA (1) CA3110414A1 (cg-RX-API-DMAC7.html)
IL (1) IL281043A (cg-RX-API-DMAC7.html)
WO (1) WO2020037434A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3991748A3 (en) 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
PT3380495T (pt) * 2015-11-24 2021-08-19 Transfert Plus Sec Compostos peptídicos e conjugados peptídicos para o tratamento de cancro através de quimioterapia mediada por recetores
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
SMT202300110T1 (it) 2018-07-13 2023-05-12 Alector Llc Anticorpi anti-sortilina e relativi metodi di uso
CN117320756A (zh) * 2021-02-26 2023-12-29 特拉斯福特普拉斯公司 用于靶向癌干细胞的方法和结合分拣蛋白的缀合化合物
CA3208147A1 (en) * 2021-02-26 2022-09-01 Richard Beliveau Methods and compounds for targeting cancer stem cells
CN116731113A (zh) * 2022-03-01 2023-09-12 上海智肽生物科技有限公司 针对sort1的多肽化合物及其药物偶联物
US20250345446A1 (en) 2022-06-23 2025-11-13 Draupnir Bio Aps Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes
WO2024103161A1 (en) * 2022-11-14 2024-05-23 Theratechnologies Inc. Drug conjugate compounds for stimulating the antitumor immune response
CN122249236A (zh) * 2023-09-11 2026-06-19 瑟瑞技术公司 喜树碱类似物的肽缀合物及其用途
WO2025208212A1 (en) * 2024-04-02 2025-10-09 Theratechnologies Inc. Combination therapies comprising peptide-drug conjugates targeting sortilin
WO2025236098A1 (en) * 2024-05-16 2025-11-20 Theratechnologies Inc. Peptide conjugates of maytansinoids and uses thereof
TW202604936A (zh) * 2024-07-25 2026-02-01 大陸商上海湃鴻生物科技有限公司 一種多肽藥物偶聯物及其製備方法和應用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017088058A1 (en) 2015-11-24 2017-06-01 Transfert Plus, S.E.C. Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3302488B1 (en) * 2015-06-03 2020-09-30 Tairx, Inc. Novel use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017088058A1 (en) 2015-11-24 2017-06-01 Transfert Plus, S.E.C. Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy

Also Published As

Publication number Publication date
AU2019324747A1 (en) 2021-04-01
JP2021535209A (ja) 2021-12-16
EP3844190A1 (en) 2021-07-07
WO2020037434A1 (en) 2020-02-27
IL281043A (en) 2021-04-29
CN113286820A (zh) 2021-08-20
CA3110414A1 (en) 2020-02-27
CN113286820B (zh) 2025-04-08
EP3844190A4 (en) 2022-06-08
US20220000971A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
CN113286820B (zh) 用于靶向分拣蛋白受体和抑制血管生成拟态的方法和化合物
JP7158547B2 (ja) Muc1に特異的に結合する抗体及びその用途
TWI772288B (zh) 基於艾日布林之抗體-藥物結合物及使用方法
JP7863808B2 (ja) がんを有する対象においてがんを処置することに用いるための抗meflin抗体、および当該抗体を含む医薬組成物
JP2019501141A (ja) 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート
Liu et al. High antitumor activity of Sortase A-generated anti-CD20 antibody fragment drug conjugates
JP7659326B2 (ja) ヒト化抗gpc-1抗体
US20250312468A1 (en) Anti-protac antibodies and complexes
EP4491632A1 (en) Ror1-targeted binding molecule and use thereof
WO2021251460A1 (ja) Cafを有するがんを処置するための組成物
CA3254345A1 (en) Ror1-targeted binding molecule and use thereof
EP4642482A1 (en) Vhh anti-protac antibodies and complexes
HK40117209A (zh) 一种靶向ror1的结合分子及其应用
HK40117209B (en) Ror1-targeted binding molecule and use thereof

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20210421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231030

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240619

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240708

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241022

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241113

R150 Certificate of patent or registration of utility model

Ref document number: 7592320

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150